EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in CAR-Based Solid Tumor Immunotherapy

Min Hwa Shin iD, Eunha Oh, Yunjeong Kim, Dae-Hwan Nam, So Young Jeon, Jin Hyuk Yu, Dohsik Minn iD

Cells · 11.06.2023 · 12 (12) · 1606

DOI: 10.3390/cells12121606 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.06.2023. Verfasst von Min Hwa Shin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of Korea. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in the treatment of hematological malignancies. However, their limitations in solid tumors include an immunosuppressive tumor microenvironment (TME), insufficient tumor infiltration, toxicity, and the absence of tumor-specific antigens. Although recent advances in CAR-T cell design—such as the incorporation of co-stimulatory domains and the development of armored CAR-T cells—have shown promising results in treating solid tumors, there are still challenges that need to be addressed. To overcome these limitations, other immune cells, such as natural killer (NK) cells and macrophages (M), have been developed as attractive options for efficient cancer immunotherapy of solid tumors. CAR-NK cells exhibit substantial clinical improvements with "off-the-shelf" availability and low toxicity. CAR-M cells have promising therapeutic potential because macrophages can infiltrate the TME of solid tumors. Here, we review the recent advances and future perspectives associated with engineered immune cell-based cancer immunotherapies for solid tumors. We also summarize ongoing clinical trials investigating the safety and efficacy of engineered immune cells, such as CAR-T, CAR-NK, and CAR-M, for targeting solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansImmunotherapy, AdoptiveImmunotherapyT-LymphocytesAntigens, NeoplasmTumor Microenvironment

Stichwörter der Autor:innen

CAR-MCAR-NKCAR-Tcancer immunotherapy

Substanzen

Receptors, Chimeric AntigenAntigens, Neoplasm

Autor:innen und Institutionen

  • Immune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of Korea.
  • Department of Diagnostic Immunology, Seegene Medical Foundation, Seoul 04805, Republic of Korea.

ORCID-Profile: Min Hwa Shin, Dohsik Minn

Zitieren

APA

Shin, M. H., Oh, E., Kim, Y., Nam, D. H., Jeon, S. Y., Yu, J. H., & Minn, D. (2023). Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells, 12(12), 1606. https://doi.org/10.3390/cells12121606

Vancouver

Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, et al. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells. 2023;12(12):1606. doi:10.3390/cells12121606

BibTeX
@article{Shin2023,
  author = {Shin, Min Hwa and Oh, Eunha and Kim, Yunjeong and Nam, Dae-Hwan and Jeon, So Young and Yu, Jin Hyuk and Minn, Dohsik},
  title = {Recent Advances in CAR-Based Solid Tumor Immunotherapy},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {1606},
  doi = {10.3390/cells12121606}
}
Kostenlos starten →